Kliniske studier for KOLS i Louisiana
9 studier for KOLS søker deltakere på steder i Louisiana.
Byer i Louisiana
Offisiell studietekst (engelsk)
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
- Research Site, Lafayette
- Research Site, Monroe
- Research Site, Shreveport
- og 1 flere
RekruttererFase 3
Alder 40 til 80 · Alle kjønn · Oppdatert 2. okt. 2026 · NCT06283966Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
- Ochsner LSU Health Shreveport - Academic Medical Center- Site Number : 8400083, Shreveport
- Care Access - Shreveport - Youree Drive- Site Number : 8400007, Shreveport
RekruttererFase 3
Alder 40 til 80 · Alle kjønn · Oppdatert 1. okt. 2026 · NCT07190222Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
- Southern Clinical Research - Zachary- Site Number : 8400113, Zachary
RekruttererFase 3
Alder 40 til 80 · Alle kjønn · Oppdatert 22. sep. 2026 · NCT07190209A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-1)
- GSK Investigational Site, Lake Charles
RekruttererFase 3
Alder 40 til 80 · Alle kjønn · Oppdatert 9. sep. 2026 · NCT07780669A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
- Research Site, Zachary
RekruttererFase 2
Alder 40 og eldre · Alle kjønn · Oppdatert 9. sep. 2026 · NCT07082738A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
- Southern Clinical Research, LLC, Zachary
RekruttererFase 2/3
Alder 35 til 80 · Alle kjønn · Oppdatert 31. aug. 2026 · NCT07363694STRIVE Post-Market Registry Study
- LSU Health Shreveport, Shreveport
RekruttererObservasjonsstudie
Alder 18 og eldre · Alle kjønn · Oppdatert 3. aug. 2026 · NCT04302272eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
- GSK Investigational Site, Lake Charles
- GSK Investigational Site, Shreveport
RekruttererFase 3
Alder 40 til 75 · Alle kjønn · Oppdatert 28. jul. 2026 · NCT07177339Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
- GSK Investigational Site, Baton Rouge
- GSK Investigational Site, Lafayette
- GSK Investigational Site, Shreveport
RekruttererFase 3
Alder 40 til 80 · Alle kjønn · Oppdatert 9. apr. 2026 · NCT06961214Fra ClinicalTrials.gov, data hentet 4. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.